NATCO Pharma Limited
Preview the depth — unlock the full forensic study.
You're reading the free Overview. The full Landscape study, the Lenses, governance and quality scans unlock with Pro — across 5,000 Indian companies.
Briefing
NATCO Pharma Limited — the brief
Forensic posture: Clean disclosures. The auditor gave a clean bill of health with no flags, related-party dealings are mostly routine subsidiary sales (₹12.91 Cr) though two KMPs received ₹75 Mn commissions each that warrant scrutiny, contingent liabilities sit at ₹30 Cr (0.04% of net worth, immaterial), and the earnings quality composite is excellent at 82/100 with solid cash-profit alignment and low bankruptcy risk.
Auditor’s report (CARO 2020)
Auditor’s assessment Clean. Auditor: B S R and Co. Fiscal year FY24-25.
Related-party transactions
Assessment Notable. Disclosed volume of ₹2 Cr across 21 related parties. Fiscal year FY25.
- Large commission payments to KMP: Significant commission payments of ₹75 Mn each to two KMPs (Mr. V C Nannapaneni and Mr. Rajeev Nannapaneni) warrant scrutiny regarding commercial justification and arm's-length nature.
Contingent liabilities
Assessment Routine. Total disclosed: ₹30 Cr (0.0% of net worth). Fiscal year FY25.
Corporate governance
Board of 13 directors, 62% independent. Chair: Sri V.C. Nannapaneni. Chair and CEO roles are separated. Statutory auditor: Not explicitly named in provided excerpt. Fiscal year FY24-25.
“Commission 75 75 Commission 75 75”
What retail misses·The two ₹75 Mn KMP commission payments buried in related-party disclosures don't show up in earnings headlines — they are material to understanding insider remuneration policy and warrant deeper commercial justification than the filings provide.
Strengths noted in disclosures: Auditor (B S R and Co) flagged zero high, material, or minor issues — filings are clean. · Earnings quality composite scores 82/100 (excellent) with cash flow matching profits and no earnings manipulation red flags. · Bankruptcy risk is low (Altman Z at 7.22, well into safe zone); contingent liabilities of ₹30 Cr represent just 0.04% of net worth.
Forensic signal
From the company's own filingsStrong: Valuation · Weak: 52-Week · Yield